Bulk Quote Inquiry

COV-VM3BD-100μg / Inquiry

COV-VM3BD-500μg / Inquiry

COV-VM3BD-1mg / Inquiry

SARS-COV-2 Spike RBD Protein

Product Info
Source

Recombinant SARS-COV-2 Spike RBD Protein is expressed from Expi293 with mFc at the C-terminal. It contains Arg319-Asn532.[Accession | QHD43416.1]

Molecular Weight

The protein has a predicted MW of 49.7 kDa. Due to glycosylation, the protein migrates to 60-70 kDa based on Tris-Bis PAGE result.

Endotoxin

Less than 1EU per μg by the LAL method.

Purity

> 95% as determined by Tris-Bis PAGE
> 95% as determined by SEC-HPLC

Formulation

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 5 % trehalose is added as protectant before lyophilization.

Reconstitution

Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

Storage

The product should be stored at -70℃ or -20℃.

Assay Data
Tris-Bis PAGE

SARS-COV-2 Spike RBD on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

The purity of SARS-COV-2 Spike RBD is greater than 95% as determined by SEC-HPLC.

ELISA Data

Immobilized SARS-COV-2 Spike RBD at 0.2μg/ml (100μl/Well). Dose response curve for Human ACE2, hFc Tag with the EC50 of 60.9ng/ml determined by ELISA.

Batch to Batch Consistency

Immobilized SARS-COV-2 Spike RBD at 0.2μg/ml (100μl/Well). Dose response curve for Human ACE2, hFc Tag with the EC50 of 60.9/52.6/52.6ng/ml determined by ELISA.

Background

The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Synonyms

S protein RBD,Spike glycoprotein Receptor-binding domain,S glycoprotein RBD,Spike protein RBD

References

(1)Larry J Anderson, Ralph S Baric. Emerging Human Coronaviruses - Disease Potential and Preparedness[J]. N Engl J Med, 2012, 367(19):1850-1852.

Kactus Biosystems Co.Ltd
Online Message